CNASOTCALUSTAL
STALLERGENES
Identification
- Active ingredient (INN)
- EXTRAITS ALLERGENIQUES MELANGE DE 5 GRAMINES
- Internal code
- 01 D 037
- Country of Origin
- France
- Pharmaceutical form
- Injectable Suspension
- Prescription List
- OTC
- Packaging
- b/03fl.
CNASDAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders.
It was also used formerly as a growth promoter in animals.
According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.
Indications
Used in the treatment of prostate cancer.
Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
Pharmacodynamics
Diethylstilbestrol is a synthetic estrogen that was developed to supplement a woman's natural estrogen production.
In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.
Mechanism of Action
Estrogen receptor beta Agonist Estrogen receptor Agonist Estrogen-related receptor gamma Agonist.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.